<DOC>
	<DOC>NCT02364024</DOC>
	<brief_summary>The purpose of this study is to confirm that linear quantification of CD3+ cells is a prognostic biomarker in localized colorectal carcinomas.</brief_summary>
	<brief_title>Validation Study of Linear Quantification of CD3+ Cells in Localized Colorectal Carcinomas</brief_title>
	<detailed_description>Adult patients of both gender who have underwent surgical resection of stage III colorectal carcinoma and randomised to receive a chemotherapy FOLFOX or FOLFOX + Cetuximab in the PETACC8 trial.</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Patient included in PETACC08 study Signed informed consent for translational study FFPE tumor sample available for CD3 staining Patient who have withdrawn their consent for PETACC08 and/or for PETACC08 translational study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Colon and rectum carcinoma</keyword>
	<keyword>Immune response</keyword>
	<keyword>Biomarker</keyword>
	<keyword>Prognosis</keyword>
</DOC>